Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Prinses Máxima Centrum Voorpagina
Nederlands
English
Voorpagina
Profielen
Onderzoeksgroepen
Uitrusting
Onderzoeksoutput
Prijzen
Activiteiten
Knipsels
Zoeken op expertise, naam of affiliatie
Reproductive status in adult male long-term survivors of childhood cancer
K. Tromp
, J. J.M. Claessens
, S. L. Knijnenburg
,
H. J.H. Van Der Pal
, F. E. Van Leeuwen
, H. N. Caron
, C. C.M. Beerendonk
,
L. C.M. Kremer
Onderzoeksoutput
:
Bijdrage aan tijdschrift
›
Artikel
›
peer review
31
Citaten (Scopus)
Overzicht
Vingerafdruk
Vingerafdruk
Duik in de onderzoeksthema's van 'Reproductive status in adult male long-term survivors of childhood cancer'. Samen vormen ze een unieke vingerafdruk.
Sorteer per
Gewicht
Alfabetische volgorde
Keyphrases
Childhood Cancer Survivors
100%
Long-term Survivors
100%
Adult Male
100%
FSH Level
100%
Reproductive Status
100%
Assisted Reproductive Technology
71%
Elevated FSH
57%
Treatment-related
42%
Related Risk Factors
42%
Male Survivors
42%
Testosterone
28%
Adulthood
28%
First Visit
28%
Endocrine Function
28%
Outpatient Clinic
28%
Reproductive Endocrine
28%
Follow-up Time
14%
Predictive Value
14%
Cancer Therapy
14%
Survivors
14%
Diagnostic Value
14%
Cyclophosphamide
14%
Vinca Alkaloids
14%
Alkylating Agents
14%
Regression Analysis
14%
Birthday
14%
Young Males
14%
5-year Survivors
14%
Pregnancy Outcome
14%
Live Birth
14%
Patient Characteristics
14%
Total Body Irradiation
14%
Procarbazine
14%
Negative Predictive Value
14%
Hypergonadotropic Hypogonadism
14%
LH Level
14%
Treatment Characteristics
14%
Prevalence Rate
14%
Abdominal Irradiation
14%
Treatment Initiation
14%
All-male
14%
18th
14%
Medicine and Dentistry
Childhood Cancer
100%
Assisted Reproductive Technology
100%
Conception
40%
Outpatient
40%
Diagnosis
20%
Prevalence
20%
Cohort Analysis
20%
Cyclophosphamide
20%
Alkylating Antineoplastic Agent
20%
Vinca Alkaloid
20%
Whole Body Radiation
20%
Procarbazine
20%
Pelvis
20%
Hypergonadotropic Hypogonadism
20%
Long Term Effect of Cancer Therapy
20%